Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 10/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13067962 | 0.92 | TP53 (0.36) | CCR5UBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2884715 | 0.91 | CCR5 (0.44) | CCR5UBE2MDCUN1D1AHCY | |
| SCHEMBL2888718 | 0.84 | MGLL (0.51) | UBE2MDCUN1D1KDRLMNA | |
| SCHEMBL13067963 | 0.83 | CCR5 (0.39) | CCR5UBE2MDCUN1D1LMNA | |
| SCHEMBL2890633 | 0.83 | L3MBTL1 (0.41) | LMNAL3MBTL1 | |
| SCHEMBL2888423 | 0.77 | GAA (0.47) | UBE2MDCUN1D1TP53KDR | |
| SCHEMBL2888588 | 0.76 | TSPO (0.41) | LMNAL3MBTL1 | |
| SCHEMBL13862600 | 0.75 | MGLL (0.44) | UBE2MDCUN1D1KDRLMNA | |
| SCHEMBL643168 | 0.74 | GAA (0.60) | UBE2MDCUN1D1TP53KDR | |
| SCHEMBL2888454 | 0.72 | PNLIP (0.46) | LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2220026-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009066072-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066072-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD17B13, HSD17B3, HSD3B2 | HSD17B1 6/4885HSD17B2 10/4885CCR5 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.